Documents

Strong Q2 growth, margin expansion, and new product launches position for continued outperformance.

Q1 2026 delivered 87% revenue growth, margin gains, and net debt reduction after a major capital increase.

Market leader with strong growth, innovation, and broad branded portfolio in Brazilian pharma.

2025 saw accelerated growth, record cash flow, and strong positioning for 2026 launches.

Strong retail growth, record cash flow, and robust pipeline position for future expansion.

Sell-out outpaced the market, margins improved, and focus shifts to deleveraging and growth.

Sell-out up 7%, revenue down 41%, record cash flow, margins to normalize in Q2.

Net revenue declined 6% amid inventory optimization, with margin recovery expected in H2 2024.

Q3 2024 saw accelerated sell-out, strong cash flow, and ongoing inventory optimization.

Working capital optimization targets BRL 7.5 billion cash gain in 10 years, with short-term margin impact.

Strong Q2 growth in chronic treatments and cash flow, with positive outlook for H2 2024.